cellcentric.com Report : Visit Site

Technical data of the cellcentric.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host cellcentric.com. Currently, hosted in United Kingdom and its service provider is DigitalOcean London .

the related websites

chesterfordresearchpark.com oxfordsp.com bloomberg.com morningadvertiser.co.uk transparency.org microbeworld.org telegraph.co.uk evalued.bcu.ac.uk thetimes.co.uk moneysupermarket.com apple.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx/1.4.6 (Ubuntu) containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

cellcentric skip to content company ccs1477 team investors news contact ccs1477, a first-in-class small molecule to treat prostate (crpc) and other cancers p300/cbp bromodomain inhibitor ccs1477 our science ccs1477 inhibits the bromodomains of twin histone acetyl transferase proteins, p300/cbp there is a large and growing population of prostate cancer patients that are resistant to second generation anti-hormonal drugs. ccs1477 addresses this through lowering the key drivers of this resistance and late stage disease: ar, ar-sv and c-myc. other cancer tumours are also susceptible to p300/cbp inhibition, notably specific haematological, bladder and lung cancers. backed by strong pre-clinical data, ccs1477 is now heading to clinical trials. cellcentric’s scientific foundation is in epigenetics. having originally spun out of the university of cambridge, the company has investigated over 50 epigenetic-related targets before focusing on p300/cbp. more on ccs1477 aacr, chicago (2018) novel small molecule inhibitor of p300/cbp down-regulates androgen receptor (ar) and c-myc for the treatment of prostate cancer and beyond aacr-prostate, orlando (2017) therapeutic targeting of the p300/cbp bromodomain for the treatment of castration resistant prostate cancer (crpc) pcf, washington dc (2017) targeting the bromodomain of p300/cbp for the treatment of castrate resistant prostate cancer asco, chicago (2017) characterisation of ccs1477: a novel mall molecule inhibitor of p300/cbp for the treatment of crpc aacr, washington dc (2017) novel small molecule inhibitors of p300/cbp down-regulate ar and c-myc for the treatment of crpc gu-asco, orlando (2017) a novel small molecule inhibitor of p300/cbp for the treatment of crpc – preclinical evaluation our team cellcentric’s team has deep experience of drug discovery and development in oncology the company is supported by a strong network of clinical, scientific and commercial advisors. cellcentric also actively collaborates with a number of world-leading cancer research centres, on the effects of ccs1477 and p300/cbp inhibition. meet the team press releases see more cellcentric raises $26 million to take first-in- class p300/cbp inhibitor into the clinic may 15th 2018 cellcentric has raised $26 million in private financing to fund clinical testing of its first-in-class oncology drug candidate ccs1477. the funds will be used to test the novel p300/cbp inhibitor in late stage, treatment-resistant prostate cancer (up to phase iib). recent data shared at aacr also highlighted the potential of ccs1477 in a range of cancers, and these will be explored additionally. the further funds come from one of cellcentric’s existing investors, morningside venture investments. read more cellcentric at aacr 2018: first-in-class p300/cbp inhibitor drug candidate, for prostate cancer and beyond april 17th 2018 cellcentric’s oral drug candidate ccs1477 addresses the large and growing population of late stage prostate cancer patients who have inherent or acquired resistance to current second-line anti-androgen therapies. it can be used after or in combination with abiraterone (zytiga), enzalutamide (xtandi) and apalutamide (erleada). new pre-clinical data is presented today at the annual american association of cancer research (aacr) meeting, chicago, supporting its targeted use not just for prostate cancer (crpc), but also for other indications including certain haematological cancers (aml and multiple myeloma). read more cellcentric’s first-in-class p300/cbp inhibitor drug ccs1477; capsule production complete ready for the clinic march 7th 2018 production of ccs1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical trials to investigate the novel drug’s tolerability and efficacy in treating late stage prostate cancer (crpc). the active component is a p300/cbp bromodomain inhibitor that has a profound effect on the drivers of cprc. it addresses the resistance seen in tumours treated with current second generation anti-hormonal drugs. formulation and gmp manufacture of the capsules was carried out by quay pharma. read more see more twitter ( follow us ) clinical plan: ccs1477 for prostate (crpc) and other cancers. pic.twitter.com/qcnqikx3wq reply to this tweet retweet this tweet like this tweet view tweet cellcentric heading to chicago for asco. ccs1477 for prostate (crpc) and other cancers. pic.twitter.com/xakpb63uyn reply to this tweet retweet this tweet like this tweet view tweet ccs1477 first-in-class p300/cbp inhibitor for prostate (crpc) and other cancers pic.twitter.com/g74rxd1uli reply to this tweet retweet this tweet like this tweet view tweet thank you apconix. ccs1477 successfully steered through pre-clin tox; onward to the clinic. pic.twitter.com/ntpxtu1m7s reply to this tweet retweet this tweet like this tweet view tweet follow us © 2007-2018 cellcentric designed and built by onespacemedia

URL analysis for cellcentric.com

http://www.cellcentric.com///cellcentric-programme/
http://www.cellcentric.com///media/uploads/files/brooks_pcf_poster_final_3_3grcjn6.pdf
http://www.cellcentric.com///press-releases/2018/may/15/cellcentric-raises-26-million-take-first-class-p30/
http://www.cellcentric.com///media/uploads/files/cellcentric_aacr_poster_2018.pdf
http://www.cellcentric.com///meet-the-team/
http://www.cellcentric.com///media/uploads/files/asco_poster_2017_final.pdf
http://www.cellcentric.com//#main
http://www.cellcentric.com///media/uploads/files/asco-gu_poster_final.pdf
http://www.cellcentric.com///press-releases/2018/apr/17/cellcentric-aacr-2018-first-class-p300cbp-inhibito/
http://www.cellcentric.com///contact-us/
http://www.cellcentric.com///company/
http://www.cellcentric.com///press-releases/2018/mar/7/cellcentrics-first-class-p300cbp-inhibitor-drug-cc/
http://www.cellcentric.com///cellcentric-programmes/
http://www.cellcentric.com///ccs1477/
http://www.cellcentric.com///investors/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: cellcentric.com
Registry Domain ID: 105996082_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.registrationtek.com
Registrar URL: https://www.registrationtek.com/whois-i/regtek_whois.php
Updated Date: 2013-10-02T10:56:01Z
Creation Date: 2003-11-02T19:21:55Z
Registrar Registration Expiration Date: 2018-11-02T18:21:55Z
Registrar: Registration Technologies, Inc.
Registrar IANA ID: 321
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.4016482137
Domain Status: OK https://icann.org/epp#OK
Registry Registrant ID:
Registrant Name: Will West
Registrant Organization: CellCentric Limited
Registrant Street: Chesterford Research Park
Registrant City: Little Chesterford
Registrant State/Province: Cambridge
Registrant Postal Code: CB10 1XL
Registrant Country: GB
Registrant Phone: +44.1799531130
Registrant Phone Ext:
Registrant Fax:
Registrant Fax Ext:
Registrant Email: [email protected]
Registry Admin ID:
Admin Name: Will West
Admin Organization: CellCentric Limited
Admin Street: Chesterford Research Park
Admin City: Little Chesterford
Admin State/Province: Cambridge
Admin Postal Code: CB10 1XL
Admin Country: GB
Admin Phone: +44.1799531130
Admin Phone Ext:
Admin Fax:
Admin Fax Ext:
Admin Email: [email protected]
Registry Tech ID:
Tech Name: Will West
Tech Organization: CellCentric Limited
Tech Street: Chesterford Research Park
Tech City: Little Chesterford
Tech State/Province: Cambridge
Tech Postal Code: CB10 1XL
Tech Country: GB
Tech Phone: +44.1799531130
Tech Phone Ext:
Tech Fax:
Tech Fax Ext:
Tech Email: [email protected]
Name Server: NS1.LIVEDNS.CO.UK
Name Server: NS2.LIVEDNS.CO.UK
Name Server: NS3.LIVEDNS.CO.UK
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-07-19T00:38:28Z <<<

For more information on Whois status codes, please visit https://icann.org/epp


  REGISTRAR REGISTRATION TECHNOLOGIES, INC.

  REFERRER http://www.RegistrationTek.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =cellcentric.com

  PORT 43

  SERVER whois.registrationtek.com

  ARGS cellcentric.com

  PORT 43

  TYPE domain

DOMAIN

  NAME cellcentric.com

NSERVER

  NS1.LIVEDNS.CO.UK 213.171.192.250

  NS2.LIVEDNS.CO.UK 213.171.193.250

  NS3.LIVEDNS.CO.UK 213.171.192.254

STATUS
ok https://icann.org/epp#ok

  CHANGED 2013-10-02

  CREATED 2003-11-02

  EXPIRES 2018-11-02

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .